Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Feasibility Testing of Decision Support for Patients Who Are Candidates for an Implantable Defibrillator

16 mars 2016 uppdaterad av: Sandra Carroll, McMaster University

Development of and Feasibility Testing of Decision Support for Patients Who Are Candidates for an Implantable Defibrillator

Sudden cardiac death (SCD) due to a ventricular arrhythmia is a serious cause of cardiovascular death in Canada. The implantable cardioverter defibrillator (ICD) offers high-risk patients a treatment option to reduce the incidence of SCD by delivering an internal shock to restore a normal rhythm, if needed. Definitive evidence has established the effectiveness of the ICD for reducing mortality when used as prophylaxis for SCD (a primary prevention indication). Approximately 3,700 new candidates accrue annually. Practice guidelines define the criteria to determine patient ICD candidacy for primary prevention. However, in addition to SCD risk, ICD candidates may have chronic diseases such as diabetes, renal insufficiency, hypertension, and atrial fibrillation. Thus, balancing the benefits and risks of an ICD can become complex, particularly when competing mortality risks are present. Research has recognized human costs associated with device complications and shocks affecting psychological, health related quality of life (HRQL), and morbidity outcomes. The complexities surrounding the long-term benefits/risks, complications, replacements, and shocks, warrant decision support to prepare patients to make decisions. In Canada, there is no clear framework to support patients' decision-making in the context of ICD treatment options. Decision support, using a decision aid, could moderate treatment related uncertainty and prepare patients to make active, informed, quality decisions.

Objectives: 1) develop a decision aid for ICD candidates to support quality decision-making (informed, deliberate, values-based choices), 2) to evaluate the decision aid, and 3) to determine the feasibility of conducting a trial.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Faktisk)

82

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Ontario
      • Hamilton, Ontario, Kanada, L8P 2X2
        • Hamilton Health Sciences

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Referred for consideration of an ICD(non-CRT)for a primary prevention indication
  • English speaking
  • able to provide informed consent

Exclusion Criteria:

  • unable to understand the decision aid due to a language barrier or visual impairment
  • referred for secondary prevention indication

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Hälsovårdsforskning
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Patient Decision Aid for an ICD (primary prevention, non-CRT)
The intervention group will receive the PtDA, which provides a lay summary that outlines the facts, risks, benefits (including probabilities), specific to the option of an implantable defibrillator or the option of medical management to prepare them for consultation with the physician. Values are assessed to reveal which features of each option are important to patients.
The intervention group will receive the PtDA, which provides a lay summary that outlines the facts, risks, benefits (including probabilities), specific to the option of an implantable defibrillator or the option of medical management to prepare them for consultation with the physician. Values are assessed to reveal which features of each option are important to patients.
Andra namn:
  • PtDA
Inget ingripande: Usual care
The control group will not receive the patient decision aid prior to consultation with the physician.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Primary Outcomes(composite): i) decision aid development, and ii) decision aid evaluation.
Tidsram: Phase 1-2 (1- year)
Development of the decision aid will be guided by the Ottawa Decision Support Framework (ODSF). Evaluation will include the Decision Aid Acceptability questionnaire comprised of 10 items including comprehensibility, balance of presentation of information, and overall suitability.
Phase 1-2 (1- year)

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Pilot RCT (feasibility)
Tidsram: Pre-Post consultation - participants will be followed until consultation is completed and at 3 months post consultation (average of 16 weeks)
In this feasibility RCT, the feasibility regarding processes (referral and recruitment rates, consent), key to the success of a larger study will be assessed. This includes successful delivery of the decision aid in an efficient manner, the monitoring of resources (budget), and study management (trial coordination, human resources). We will assess the proportion of patients who complete the decision aid, quality questionnaires, and missing data.
Pre-Post consultation - participants will be followed until consultation is completed and at 3 months post consultation (average of 16 weeks)
Decision quality measures
Tidsram: Pre consultation (baseline visit)
Decision quality, the extent to which patients' decisions are informed (knowledge) and values based (values, preferences, decisional conflict).
Pre consultation (baseline visit)
Decisional Conflict Scale (DCS)
Tidsram: Pre and post consultation- (intervention and usual care group, baseline visit + 1 week post consult)
The Decisional Conflict Scale measures a person's perception of the difficulty in making a decision, the extent to which they feel uncertain about treatment options, are knowledgeable about the risks and benefits of options, clear about personal values, and supported in decision making. The scale has good test-retest reliability (Cronbach's alpha coefficients > 0.78) and predictive validity.
Pre and post consultation- (intervention and usual care group, baseline visit + 1 week post consult)
Sure Test
Tidsram: Pre-consultation - baseline visit
The Sure Test is a 4 item decisional conflict screening tool designed for use in clinical practice. The Sure Test is embedded in the decision aid (intervention group).
Pre-consultation - baseline visit
The Center for Epidemiologic Studies Depression Scale (CES-D)
Tidsram: Pre consultation - baseline visit (intervention and usual care)
The CES-D has 20 items that measure depressive symptoms. The CES-D has good reliability and validity across community and clinical settings. Associations between depressive symptoms and decision choice will be assessed.
Pre consultation - baseline visit (intervention and usual care)
Preparation for Decision Making scale
Tidsram: Post consultation - up to two weeks post baseline visit (intervention group)
The Preparation for Decision Making Scale has 10 categorical items assessing the usefulness of the decision aid in preparing patients to communicate with a health professional.
Post consultation - up to two weeks post baseline visit (intervention group)
The Medical Outcomes Trust Short Form (SF-36v2)
Tidsram: Pre consultation - baseline visit (intervention and usual care)
The SF-36 is a reliable and valid generic health related quality of life scale (HRQL) comprised of 36 items. Associations between HRQL and decision choice will be undertaken.
Pre consultation - baseline visit (intervention and usual care)

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Vital status
Tidsram: 3 months post baseline visit
Alive, deceased
3 months post baseline visit
Implant status
Tidsram: Phase 3, three months post baseline visit
Device status - implantable defibrillator/no implantable defibrillator, deferred
Phase 3, three months post baseline visit

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Sandra L Carroll, PhD, McMaster University

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Användbara länkar

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart

1 juni 2012

Primärt slutförande (Faktisk)

1 september 2014

Avslutad studie (Faktisk)

1 december 2014

Studieregistreringsdatum

Först inskickad

30 maj 2013

Först inskickad som uppfyllde QC-kriterierna

11 juni 2013

Första postat (Uppskatta)

12 juni 2013

Uppdateringar av studier

Senaste uppdatering publicerad (Uppskatta)

17 mars 2016

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

16 mars 2016

Senast verifierad

1 mars 2016

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • 12-214
  • 119449 Grant number (Annat bidrag/finansieringsnummer: Canadian Institutes of Health Research)

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

3
Prenumerera